LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
LeMaitre Vascular Price Performance
Shares of LMAT opened at $103.74 on Wednesday. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of 56.69, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1 year low of $51.70 and a 1 year high of $106.49. The business's 50 day simple moving average is $92.45 and its 200-day simple moving average is $86.15.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. During the same period in the prior year, the firm earned $0.33 EPS. The company's revenue for the quarter was up 15.6% on a year-over-year basis. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.
LeMaitre Vascular Dividend Announcement
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold | Ad
Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio (DPR) is currently 34.97%.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. CANADA LIFE ASSURANCE Co boosted its holdings in LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier's stock valued at $1,472,000 after acquiring an additional 6,875 shares during the period. Quadrature Capital Ltd boosted its holdings in LeMaitre Vascular by 129.4% during the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier's stock valued at $1,484,000 after acquiring an additional 12,654 shares during the period. Janus Henderson Group PLC boosted its holdings in LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier's stock valued at $3,697,000 after acquiring an additional 47,218 shares during the period. Sequoia Financial Advisors LLC purchased a new position in LeMaitre Vascular during the 2nd quarter valued at $1,010,000. Finally, Harbor Capital Advisors Inc. boosted its holdings in LeMaitre Vascular by 240.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier's stock valued at $929,000 after acquiring an additional 7,976 shares during the period. Institutional investors own 84.64% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price target on the stock. JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 20th. Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a "buy" rating and a $105.00 price target on the stock. Finally, Oppenheimer reissued an "outperform" rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $94.57.
Read Our Latest Stock Analysis on LMAT
About LeMaitre Vascular
(
Get Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
